SkinBioTherapeutics Income Statement

Financials in millions GBP. Fiscal year is July - June.

Millions GBP. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021
Operating Revenue	4.64	1.21	0.13	0.07	-
Revenue	4.64	1.21	0.13	0.07	-
Revenue Growth (YoY)	283.74%	815.26%	76.64%	-	-
Cost of Revenue	1.78	0.53	0.05	0.03	-
Gross Profit	2.86	0.68	0.09	0.05	-
Selling, General & Admin	3.86	3.03	2.15	2.17	0.99
Research & Development	0.13	0.56	0.93	0.86	0.51
Operating Expenses	3.98	3.59	3.08	3.03	1.5
Operating Income	-1.12	-2.91	-3	-2.98	-1.5
Interest Expense	-0.09	-0.04	-0.01	-0.01	-0
EBT Excluding Unusual Items	-1.22	-2.95	-3.01	-2.99	-1.5
Other Unusual Items	0.5	-	-	-	-
Pretax Income	-0.72	-2.95	-3.01	-2.99	-1.5
Income Tax Expense	-0.02	-0.07	-0.17	-0.2	-0.07
Net Income	-0.7	-2.88	-2.84	-2.79	-1.43
Net Income to Common	-0.7	-2.88	-2.84	-2.79	-1.43
Shares Outstanding (Basic)	228	186	165	157	147
Shares Outstanding (Diluted)	228	186	165	157	147
Shares Change (YoY)	22.32%	13.10%	5.06%	6.87%	14.53%
EPS (Basic)	-0.00	-0.02	-0.02	-0.02	-0.01
EPS (Diluted)	-0.00	-0.02	-0.02	-0.02	-0.01
Free Cash Flow	-1.24	-2.74	-2.73	-2.67	-1.56
Free Cash Flow Per Share	-0.01	-0.01	-0.02	-0.02	-0.01
Gross Margin	61.65%	56.51%	64.51%	60.64%	-
Operating Margin	-24.21%	-240.36%	-2271.26%	-3988.83%	-
Profit Margin	-15.01%	-237.95%	-2146.91%	-3735.37%	-
Free Cash Flow Margin	-26.76%	-226.80%	-2071.02%	-3575.44%	-
EBITDA	-0.82	-2.77	-2.99	-2.98	-1.5
EBITDA Margin	-17.65%	-229.38%	-	-	-
D&A For EBITDA	0.3	0.13	0.01	0	0
EBIT	-1.12	-2.91	-3	-2.98	-1.5
EBIT Margin	-24.21%	-240.36%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.